Does Rallies show 13F holders for NKTR?

Yes. Rallies tracks hedge fund and 13F ownership data for NKTR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NKTR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.

NKTR (Nektar Therapeutics) Stock Analysis - Hedge Fund Holdings

Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of May 21, 2026, NKTR trades at $69.51 with a market cap of $2.31B and a P/E ratio of -8.33. NKTR moved +2.89% today. Year to date, NKTR is +56.26%; over the trailing twelve months it is +574.24%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is strong buy with an average price target of $153.71. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NKTR stock?

Hedge funds tracked by Rallies that own NKTR include Orbimed Advisors, Centerbook Partners, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nektar Therapeutics.

NKTR Key Metrics

Key financial metrics for NKTR
Metric	Value
Price	$69.51
Market Cap	$2.31B
P/E Ratio	-8.33
EPS	$-8.23
Dividend Yield	0.00%
52-Week High	$109.00
52-Week Low	$6.48
Volume	8
Avg Volume	0
Revenue (TTM)	$55.63M
Net Income	$-158.10M
Gross Margin	0.00%

Top Hedge Funds Holding NKTR

Orbimed Advisors holds 275.00K shares of NKTR, changed +0.00% as of Mar 31, 2026.
Centerbook Partners holds 7.41K shares of NKTR, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 4.00K shares of NKTR, changed -99.75% as of Mar 31, 2026.
Mangrove Partners holds 3.06K shares of NKTR, changed +0.00% as of Mar 31, 2026.

Latest NKTR News

Nektar Therapeutics closes $373.8 M offering, reports $44.9 M Q1 net loss, advances Phase 3 — May 7, 2026
Nektar Therapeutics Sells 4.06M Shares at $92 to Raise $373.8M — Apr 23, 2026
Nektar Gains 18% After Alopecia Trial Win and $250M Offering — Apr 21, 2026
Nektar Therapeutics posts 26-28% alopecia trial response, shares surge 21.5%, PT to $185 — Apr 20, 2026
Rezpegaldesleukin Shows Broad EASI Efficacy, 28.2% SALT Reduction And Q2 2026 Phase 3 Start — Mar 28, 2026

Recent NKTR Insider Trades

Zalevsky Jonathan sold 180 (~$13.14K) on Feb 18, 2026.
ROBIN HOWARD W sold 423 (~$30.88K) on Feb 18, 2026.
Zalevsky Jonathan sold 3.87K (~$137.94K) on Jan 20, 2026.

NKTR Analyst Consensus

9 analysts cover NKTR: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $153.71.

Common questions about NKTR

Who owns NKTR stock?: Hedge funds tracked by Rallies that own NKTR include Orbimed Advisors, Centerbook Partners, Farallon Capital, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Nektar Therapeutics.
Does Rallies show 13F holders for NKTR?: Yes. Rallies tracks hedge fund and 13F ownership data for NKTR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NKTR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.